Brief: Belite Bio Announces China NMPA Agrees To New Drug Application With Priority Review Based On Interim Analysis Results For The Treatment Of Stargardt Disease With Tinlarebant
15/10/2025 13:08
Oct 15 (Reuters) - Belite Bio Inc BLTE.O: BELITE BIO ANNOUNCES CHINA NMPA AGREES TO NEW DRUG APPLICATION WITH PRIORITY REVIEW BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT BELITE BIO INC - FINAL TOPLINE DATA FROM PHASE 3 DRAGON TRIAL EXPECTED Q4 2025 Source text: ID:nGNXbn4BQh Further company coverage: BLTE.O
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses